Repare Therapeutics Company Insiders

RPTX Stock  USD 2.65  0.00  0.00%   
Slightly above 67% of Repare Therapeutics' corporate insiders are selling. The analysis of the overall insider sentiment regarding Repare Therapeutics suggests that many insiders are alarmed. Repare Therapeutics employs about 129 people. The company is managed by 16 executives with a total tenure of roughly 301 years, averaging almost 18.0 years of service per executive, having 8.06 employees per reported executive.

Insider Sentiment 33

 Mostly Selling

 
Selling
 
Buying

Latest Trades

2024-04-01Steve ForteDisposed 789 @ 4.61View
2024-03-27Steve ForteDisposed 825 @ 4.62View
2024-03-25Steve ForteDisposed 825 @ 4.79View
2023-11-15Bvf Partners L P/IlAcquired 931556 @ 5View
2023-11-02Bvf Partners L P/IlAcquired 783709 @ 3.6View
2023-06-06Michael ZindaDisposed 1200 @ 12.04View
Monitoring Repare Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

Repare Therapeutics' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Repare Therapeutics' future performance. Based on our forecasts, it is anticipated that Repare will maintain a workforce of slightly above 130 employees by March 2026.
 
Covid
 
Interest Hikes

Repare Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.2972) % which means that it has lost $0.2972 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4978) %, meaning that it created substantial loss on money invested by shareholders. Repare Therapeutics' management efficiency ratios could be used to measure how well Repare Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.45 in 2026. Return On Capital Employed is likely to drop to -0.58 in 2026. At this time, Repare Therapeutics' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 9.4 M in 2026, whereas Net Tangible Assets are likely to drop slightly above 173 M in 2026.
Common Stock Shares Outstanding is likely to drop to about 37 M in 2026. Net Loss is likely to drop to about (27.4 M) in 2026Repare Therapeutics owns a total of 43.11 Million outstanding shares. Over half of Repare Therapeutics' outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
 
Shares in Circulation  
First Issued
2019-03-31
Previous Quarter
42.9 M
Current Value
43.1 M
Avarage Shares Outstanding
36.7 M
Quarterly Volatility
9.4 M
 
Covid
 
Interest Hikes
Some institutional investors establish a significant position in stocks such as Repare Therapeutics in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Repare Therapeutics, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Repare Therapeutics Workforce Comparison

Repare Therapeutics is currently regarded as top stock in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 728. Repare Therapeutics retains roughly 129 in number of employees claiming about 18% of equities under Health Care industry.

Repare Therapeutics Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Repare Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Repare Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Repare Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Covid
 
Interest Hikes
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2025-03-01
2.0
8
4
 750,000 
 37,270 
2024-06-01
2.0
8
4
 244,400 
 3,990 
2024-03-01
0.5
8
16
 574,000 
 17,700 
2023-12-01
5.5
11
2
 2,054,756 
 43,746 
2023-06-01
4.5
9
2
 269,469 
 7,604 
2022-12-01
1.0
8
8
 123,439 
 630,438 
2022-06-01
1.04
26
25
 1,331,589 
 3,030,176 
2022-03-01
8.0
8
1
 1,927,961 
 533.00 
2021-12-01
0.7
7
10
 102,052 
 110,430 
2021-09-01
0.1143
8
70
 55,636 
 792,879 
2021-06-01
0.2248
29
129
 317,595 
 2,101,390 
2021-03-01
1.3889
75
54
 889,232 
 5,452,388 
2020-12-01
0.2895
11
38
 115,304 
 1,240,304 
2020-06-01
1.9118
65
34
 39,767,019 
 28,184,590 

Repare Therapeutics Notable Stakeholders

A Repare Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Repare Therapeutics often face trade-offs trying to please all of them. Repare Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Repare Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Lloyd SegalCEO PresidentProfile
Steve CPACFO, PresidentProfile
Steve ForteExecutive CFOProfile
Robin KalleyVP RelationsProfile
Sandra AlvesSenior OfficerProfile
Joseph MDExecutive AffairsProfile
Kim SethExecutive OfficerProfile
Philip HermanEx DevelProfile
Daniel BelangerExecutive ResourcesProfile
Frank SicheriCoFounderProfile
Michael ZindaExecutive OfficerProfile
Maria MDExecutive OfficerProfile
Agnel SfeirCoFounderProfile
Paul MDVice AffairsProfile
Cameron BlackExecutive DiscoveryProfile
Daniel DurocherCoFounderProfile
String symbol = request.getParameter("s");

About Repare Therapeutics Management Performance

The success or failure of an entity such as Repare Therapeutics often depends on how effective the management is. Repare Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Repare management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Repare management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.43)(0.45)
Return On Capital Employed(0.56)(0.58)
Return On Assets(0.43)(0.45)
Return On Equity(0.64)(0.61)
Please note, the imprecision that can be found in Repare Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Repare Therapeutics. Check Repare Therapeutics' Beneish M Score to see the likelihood of Repare Therapeutics' management manipulating its earnings.

Repare Therapeutics Workforce Analysis

Traditionally, organizations such as Repare Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Repare Therapeutics within its industry.

Repare Therapeutics Manpower Efficiency

Return on Repare Therapeutics Manpower

Revenue Per Employee414.6K
Revenue Per Executive3.3M
Net Loss Per Employee656.5K
Net Loss Per Executive5.3M
Working Capital Per Employee1.1M
Working Capital Per Executive9.1M

Additional Tools for Repare Stock Analysis

When running Repare Therapeutics' price analysis, check to measure Repare Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Repare Therapeutics is operating at the current time. Most of Repare Therapeutics' value examination focuses on studying past and present price action to predict the probability of Repare Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Repare Therapeutics' price. Additionally, you may evaluate how the addition of Repare Therapeutics to your portfolios can decrease your overall portfolio volatility.